NB 301
Latest Information Update: 10 Jun 2005
At a glance
- Originator NewBiotics
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Jun 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 12 Jan 2000 Preclinical development for Cancer in USA (Unknown route)